博拓生物(688767) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of RMB 56,058.72 million, an increase of 26.80% compared to the same period last year[4] - The net profit attributable to the parent company was RMB 17,668.33 million, reflecting a growth of 65.74% year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 12,656.04 million, up 59.35% from the previous year[4] - Basic earnings per share increased to RMB 1.68, representing a growth of 68.00% compared to the previous year[4] - The company reported a significant increase in operating profit and total profit, both rising over 72% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 260,763.34 million, a 1.09% increase from the beginning of the period[6] - The equity attributable to the parent company was RMB 241,625.33 million, showing a slight increase of 0.04% from the beginning of the period[6] Business Strategy - The company focused on the POCT in vitro diagnostic segment, effectively capturing customer demand and expanding both domestic and international markets[7] - The increase in profits was also attributed to improved management and production efficiency, as well as the conversion of previously unreturned orders into revenue[8] Cautionary Note - The financial data presented are preliminary and have not yet been audited, with investors advised to be cautious regarding investment risks[10]